RxDoctor Payments Data

Salman Chohan, DO

Urology · Brandywine, MDNPI 1023305638

Payments from drug & device makers

$7,180in general payments, 2019–2025

Across 305 payments — averaging $23.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$840
  • Johnson & Johnson$603
  • Sumitomo Pharma America, Inc.$523
  • Pfizer$523
  • Endo Pharmaceuticals Inc.$355
  • Astellas Pharma US Inc$315
  • plus $4K from 40 others

What the payments were for

  • Speaking & faculty fees$1122%
  • Food & beverage$7,06898%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,180 in reported general payments places this provider in the 60th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$636,460
Medicare patients
1,099
Services billed
15,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide34$471,389
NubeqaDarolutamide23$315,761
XtandiEnzalutamide16$309,857
GemtesaVibegron66$66,227
OrgovyxRelugolix22$61,054
MyrbetriqMirabegron40$43,178
Tamsulosin Hcl604$9,658
Finasteride421$5,893
Oxybutynin Chloride ErOxybutynin Chloride169$4,768
Trospium Chloride24$3,006
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl12$2,685
NitrofurantoinNitrofurantoin Macrocrystal66$1,401
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst78$1,383
Dutasteride28$1,348
Alfuzosin Hcl ErAlfuzosin Hcl46$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$603$471,38934 claims
Astellas Pharma US IncXtandi, Myrbetriq$315$353,03456 claims
BayerNubeqa$189$315,76123 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$523$127,28188 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 274 urology providers in Maryland.

Other urology in Brandywine

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →